BAG3 Protein Modulation for Brain Protein Quality Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies have not effectively addressed the role of BAG3 protein in protein quality control for diseases or disorders of the brain, central nervous system, neurological, including traumatic injuries such as Parkinson's Disease, Alzheimer's Disease, and Traumatic Brain Injury complicated by Chronic Traumatic Encephalopathy.
Innovation Solution
The use of BAG3 protein or active fragments thereof, administered through expression vectors or other agents, to modulate the expression or amount of BAG3 molecules in target cells or tissues, thereby enhancing protein quality control and potentially serving as a therapeutic target for neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BAG3 protein modulation is used to enhance protein quality control in neurodegenerative diseases, then therapeutic efficacy is improved, but the complexity of the treatment approach increases
Solution Approach 1:
The patent uses BAG3 protein as an intermediary molecule to mediate between the administered agent (expression vector or pharmacological agent) and the target proteins involved in protein quality control. BAG3 acts as a molecular chaperone that facilitates proper protein folding, prevents aggregation, and promotes degradation of misfolded proteins through the proteasome and autophagy pathways, thereby providing therapeutic efficacy without requiring direct manipulation of complex cellular machinery.
2Reliability
If BAG3 expression is increased through expression vectors to improve protein quality control, then therapeutic benefit is achieved, but the ease of manufacture and delivery decreases
Solution Approach 1:
The expression vectors are designed to utilize the host cell's own transcriptional and translational machinery to produce BAG3 protein. Once the expression vector enters the target cells, it autonomously directs the synthesis of BAG3 without requiring external intervention or complex manufacturing processes for protein production and delivery. The system essentially serves itself by harnessing the cellular infrastructure already present in the target tissues.
3Adaptability or versatility
If pharmacological agents are used to modulate BAG3 levels, then treatment flexibility is improved, but the precision of BAG3 modulation decreases
Solution Approach 1:
The patent employs pharmacological agents that specifically target regulatory elements controlling BAG3 expression or stability. These agents modulate parameters such as transcriptional activity, mRNA stability, or protein degradation rates to achieve precise control over BAG3 levels. By changing these biochemical parameters in a controlled manner, the system achieves both flexibility in treatment approaches and precision in BAG3 modulation, avoiding the trade-off between the two.
Data Source
AI summary
BAG3 protein is used in the treatment of, for example, is Parkinson's disease, Alzheimer's disease, Amyotrophic Lateral Sclerosis, Huntington disease, Lewy body disease, vascular dementia, mixed dementia and Traumatic Brain Injury, for example, complicated by Chronic Traumatic Encephalopathy (CTE). Therapeutically effective BAG3 compositions, BAG3 uses and BAG3 methods of treatment are described.